Drug Discovery

Autobahn Therapeutics launches with $76m Series B financing to develop next generation therapies for CNS disorders

Financing co-led by ARCH Venture Partners and Cowen Healthcare Investments

MMS to support IGY Life Sciences in advancing Covid-19 antibody candidate

IGY Life Sciences has entered into a collaboration with MMS Holdings, a data-focused clinical research organisation (CRO), to advance the development of its anti-CoV-2 therapeutic antibody IgY-110.

AbbVie, HBM, UU, and EMC to develop Covid-19 antibody therapeutic

AbbVie has joined forces with Harbour BioMed (HBM), Utrecht University (UU), and Erasmus Medical Center (EMC) to develop a novel antibody therapeutic for the prevention and treatment of Covid-19.

Cullinan Oncology completes $98.5m Series B financing

Cullinan Oncology, LLC announced today the closing of a $98.5 million Series B financing, which will be used to support ongoing clinical trials across its small molecule and biologics portfolio.

Memo Therapeutics identifies potent SARS-CoV-2-neutralising antibodies from blood of recovered Covid-19 patients

Memo Therapeutics, an innovator in the field of antibody discovery and immune repertoire analysis, today announces that it has identified several SARS-CoV-2-specific virus-neutralizing antibodies with the potential for development as a Covid-19 immunotherapy.

AstraZeneca partners with Accent to develop cancer therapeutics

AstraZeneca has joined forces with Accent Therapeutics for the development and commercialisation of advanced therapeutics targeting RNA-modifying proteins (RMPs) to treat cancer.

AgeX Therapeutics, ImStem Biotechnology sign non-binding letter of intent regarding investigational MSC candidate IMS001 for Covid-19

AgeX Therapeutics, a biotechnology company developing therapeutics for human aging and regeneration, and ImStem Biotechnology, Inc., a biopharmaceutical company developing human embryonic stem cell-derived mesenchymal stem cells (hES-MSC), today announced their signing of a non-binding letter of intent for ImStem to obtain from AgeX a non-exclusive license to use AgeX’s embryonic stem cell line ESI 053 to derive ImStem’s investigational MSC product IMS001 for development in COVID-19 as well as acute respiratory distress syndrome (ARDS) due to other causes.

Codiak BioSciences collaborates with Ragon Institute to evaluate exoVACC vaccine platform in SARS-CoV-2 and HIV

Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, today announced that it has entered into two strategic collaborations with the Ragon Institute of MGH, MIT and Harvard to investigate the potential of its exoVACC vaccine platform in (1) SARS-CoV-2, the virus that causes Covid-19, and in (2) human immunodeficiency virus (HIV).

ISM Sensors for M800 and M300 Transmitters

METTLER TOLEDO Thornton M800 and M300 ISM process analytical instrumentation provides reliable, accurate measurements of conductivity/resistivity, pH/ORP, dissolved oxygen and dissolved ozone. On-board digital measurement and Intelligent Sensor Management (ISM) technology provide the utmost in convenience and control of sensor performance.